Virbac — Earnings Release 2024

Jul 8, 2024

Exceptional first-half growth and guidance raised for 2024

Public release on July 8, 2024 before market opening at 8:30 a.m. CEST

Given the very positive sales momentum observed in the first half of the year (revenue growth expected to be around 16% at constant exchange rates1 and ~11% at constant exchange rates and scope), which is set to continue in the second half of the year, as well as a particularly buoyant animal health market, 2024 revenue growth at constant exchange rates is expected to be between 12.5% and 14.5%1 (corresponding to a growth at constant exchange rates and scope now expected between 7% to 9%).

The ratio of "current operating income before depreciation of assets resulting from acquisitions'' to "revenue" should consolidate at around 16% at constant exchange rates and scope. At actual scope, the impact of the Sasaeah and Globion acquisitions should be slightly accretive on this ratio.

¹Including the impact of the acquisitions of Sasaeah in Japan and Globion in India

A lifelong commitment to animal health

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together.